| BCBS Federal Medical & Drug | 2.04.02 Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2) | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.08 Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.13 Genetic Testing for Alzheimer Disease | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.41 Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.60 JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.61 Gene Expression Profile Testing and Circulating Tumor DNA Testing for Predicting Recurrence in Colon Cancer | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.63 Use of Common Genetic Variants (Single Nucleotide Variants) to Predict Risk of Nonfamilial Breast Cancer | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.78 Molecular Markers in Fine Needle Aspiration of the Thyroid | 2025-12-01 |
| BCBS Federal Medical & Drug | 2.04.85 BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia | 2025-12-01 |